Developer docs
API playgroundTry for free, no card

Search company profiles

StrataStem

Full company profile

uuid02m6luc

Namestring
StrataStem
Legal namestring
StrataStem Ltd
Websiteurl
stratastem.com
Company typeenum
Private
Founded yearstring
-
Descriptiontext

StrataStem Ltd is a privately held UK contract research organization (CRO) that develops patient-derived induced pluripotent stem cell (iPSC) disease models focused on neurological disorders, with Alzheimer's disease as the lead indication. The company sources tissues from consented neurological disease patients, captures detailed clinical history and disease-associated genotypes (including APOE4), derives iPSCs, and differentiates them into brain cell types to build in vitro models used to study disease mechanisms, identify and validate therapeutic targets, and stratify patients for targeted drug development. Its flagship asset is a portfolio of 200 fully characterized iPSC lines derived from sporadic late-onset Alzheimer's disease patients, with confirmed pluripotency markers and normal karyotype.

The technical platform spans the full iPSC workflow: patient sourcing and tissue processing, iPSC derivation, differentiation to specific brain cell types, 3D neurosphere and blood-brain barrier culture, gene editing (knockout/knock-in, SNPs, INDELs), co-culture systems, 384-well high-content screening for drug toxicity/efficacy/potency, omics analysis for network modelling and differential gene expression, and patient stratification cohort creation. Custom companion assays are developed based on the company's internal know-how and external academic partnerships, including an Honorary Readership affiliation with the University of Manchester held by co-founder Dr. Chris Ward.

Commercially, StrataStem operates a quote-based contract services model, engaging pharmaceutical and biotechnology companies as its primary customer segment and academic research institutions as a secondary segment. The company markets globally via its website and direct business development outreach, with no public pricing, no disclosed funding rounds, and no disclosed revenue. The team visible in source data consists of co-founder/CSO Dr. Chris Ward and Business Development Manager Dr. Stephen France, suggesting a small, founder-led operating profile headquartered at the Alderley Park life science campus in Cheshire, UK.

Short descriptiontext

StrataStem Ltd is a UK-based contract research organization that develops patient-derived iPSC disease models and drug screening services for neurological diseases, primarily Alzheimer's, serving pharmaceutical, biotech, and academic clients with a 200-line characterized Alzheimer's iPSC portfolio.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMacclesfield, United Kingdom
HQ citystring
Macclesfield
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
iPSC disease models, drug discovery services, Alzheimer's research, neurological disease modeling, stem cell services
Industry3 codes
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
iPSC-based neurological drug discovery services
Social media profiles1 record
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

StrataStem is a contract research organization that develops and supplies patient-derived induced pluripotent stem cell (iPSC) disease models and runs drug discovery and pharmacology screening services for neurological disease, with a focus on Alzheimer's disease. The company's offering integrates patient sourcing, iPSC derivation, brain cell differentiation, gene editing, 3D neurosphere culture, pharmacology assay development, and omics analysis, anchored by a portfolio of 200 fully characterized iPSC lines from Alzheimer's patients with associated clinical history and genotypic data, enabling client programs in patient stratification and targeted therapeutic development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 200 fully characterized iPSC lines with detailed patient clinical history and APOE genotyping
Product overview1 text field

StrataStem is a biotech company offering a unified platform of iPSC-based disease modeling services and therapeutic discovery solutions. The core offering consists of iPSC Disease Models for identifying disease mechanisms and novel drug targets, Companion Assays for phenotype validation, and Therapeutics Screening services for drug efficacy and toxicity assessment. These are supported by modular service capabilities including patient sourcing and tissue processing, iPSC derivation, brain cell type differentiation, 3D neurosphere and blood-brain barrier culture, gene editing, co-culture systems, omics analysis, and patient stratification. The company's Alzheimer's Disease iPSC Portfolio provides 200 fully characterized cell lines for research applications.

Product and service4 records
1iPSC Disease Models
CategoryiPSC-based disease modeling services
Description

Patient-derived induced pluripotent stem cell (iPSC) disease models delivered to pharmaceutical, biotechnology, and academic clients for use in disease mechanism studies, target validation, and preclinical drug discovery, with a particular focus on neurological and neurodegenerative diseases.

2Companion Assays
CategoryAssay development and screening services
Description

Custom-developed pharmacology and disease-relevant assays run on iPSC-derived cellular models, designed to support client preclinical programs in neurological disease research and therapeutic development.

3Therapeutics Screening
CategoryDrug screening and preclinical testing services
Description

Therapeutic candidate screening services executed on StrataStem's iPSC-derived neuronal and neurological disease models, enabling clients to evaluate compounds for efficacy, toxicity, and mechanism of action in disease-relevant human cellular systems.

4Alzheimer's Disease iPSC Portfolio
CategoryPatient-derived iPSC biobank / cell line portfolio
Description

A biobank offering of 200 fully characterized induced pluripotent stem cell lines derived from Alzheimer's disease patients, each annotated with clinical history and genotypic data, supplied to clients for use in patient stratification, target validation, and targeted therapeutic development.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

A UK-based cell therapy and iPSC CDMO providing contract development and manufacturing services. Comparable as a UK-based iPSC services provider, though differentiated by CDMO focus versus StrataStem's discovery CRO model.

TypeEmerging player
Description

A gene editing company with strong capabilities in iPSC gene editing, including knockout/knock-in and TALEN-based editing. Overlaps with StrataStem's gene editing service module though focused on therapeutic development.

TypeDirect peer
Description

A specialist provider of iPSC-derived neural cell types and neural differentiation services for CNS drug discovery. Directly comparable to StrataStem's brain cell differentiation and neurological disease modeling offering.

TypeBroad incumbent
Description

A global CRO providing preclinical and translational drug discovery services including patient-derived models and in vitro screening. Adjacent to StrataStem through patient-derived disease modeling and drug screening services.

TypeDirect peer
Description

A European iPSC technology company offering iPSC-derived cell products and disease modeling services for drug discovery, including cardiac and neuronal applications. Direct competitor to StrataStem in iPSC-based disease models and contract screening services.

TypeBroad incumbent
Description

A major commercial supplier of iPSC-derived cell products and a provider of disease modeling services at scale. Competes with StrataStem through a much broader iPSC product portfolio and established pharma relationships.

TypeBroad incumbent
Description

A large global drug discovery CRO offering iPSC-based disease modeling, high-content screening, and target validation across multiple therapeutic areas. Overlaps with StrataStem's discovery services but at significantly greater scale and breadth.

TypeDirect peer
Description

A specialist iPSC-derived cell supplier focused on neural and cardiovascular cell types for drug discovery and disease modeling. Direct peer in iPSC-based disease models for neurological research applications.

TypeEmerging player
Description

Emerging iPSC platform companies offering patient-derived disease models and screening services. Comparable scale and indication focus to StrataStem as niche iPSC CROs serving pharma discovery.

TypeDirect peer
Description

A UK-based contract research organization specializing in iPSC-derived models, including neural and kidney models, used for drug discovery and toxicity testing. Highly comparable CRO model and indication overlap with StrataStem.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

StrataStem

iPSC-based neurological drug discovery servicesstratastem.com

StrataStem Ltd is a UK-based contract research organization that develops patient-derived iPSC disease models and drug screening services for neurological diseases, primarily Alzheimer's, serving pharmaceutical, biotech, and academic clients with a 200-line characterized Alzheimer's iPSC portfolio.

What StrataStem does

StrataStem Ltd is a privately held UK contract research organization (CRO) that develops patient-derived induced pluripotent stem cell (iPSC) disease models focused on neurological disorders, with Alzheimer's disease as the lead indication. The company sources tissues from consented neurological disease patients, captures detailed clinical history and disease-associated genotypes (including APOE4), derives iPSCs, and differentiates them into brain cell types to build in vitro models used to study disease mechanisms, identify and validate therapeutic targets, and stratify patients for targeted drug development. Its flagship asset is a portfolio of 200 fully characterized iPSC lines derived from sporadic late-onset Alzheimer's disease patients, with confirmed pluripotency markers and normal karyotype.

The technical platform spans the full iPSC workflow: patient sourcing and tissue processing, iPSC derivation, differentiation to specific brain cell types, 3D neurosphere and blood-brain barrier culture, gene editing (knockout/knock-in, SNPs, INDELs), co-culture systems, 384-well high-content screening for drug toxicity/efficacy/potency, omics analysis for network modelling and differential gene expression, and patient stratification cohort creation. Custom companion assays are developed based on the company's internal know-how and external academic partnerships, including an Honorary Readership affiliation with the University of Manchester held by co-founder Dr. Chris Ward.

Commercially, StrataStem operates a quote-based contract services model, engaging pharmaceutical and biotechnology companies as its primary customer segment and academic research institutions as a secondary segment. The company markets globally via its website and direct business development outreach, with no public pricing, no disclosed funding rounds, and no disclosed revenue. The team visible in source data consists of co-founder/CSO Dr. Chris Ward and Business Development Manager Dr. Stephen France, suggesting a small, founder-led operating profile headquartered at the Alderley Park life science campus in Cheshire, UK.

StrataStem firmographics

Firmographics
Name
StrataStem
Legal name
StrataStem Ltd
Website
https://stratastem.com
Company type
Private
Operating status
Operating
Headcount range
1–10 employees
Short description
StrataStem Ltd is a UK-based contract research organization that develops patient-derived iPSC disease models and drug screening services for neurological diseases, primarily Alzheimer's, serving pharmaceutical, biotech, and academic clients with a 200-line characterized Alzheimer's iPSC portfolio.
Ownership category
akta.pro rank

StrataStem industry classification

Industry
Product category
iPSC-based neurological drug discovery services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • IPSC disease models
  • Drug discovery services
  • Alzheimer's research
  • Neurological disease modeling
  • Stem cell services

Where StrataStem is headquartered

Location

Headquarters

HQ city
Macclesfield
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

StrataStem business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Distribution channels1 record

Marketing channels1 record

StrataStem product offering

Product offering

Core offering

StrataStem is a contract research organization that develops and supplies patient-derived induced pluripotent stem cell (iPSC) disease models and runs drug discovery and pharmacology screening services for neurological disease, with a focus on Alzheimer's disease. The company's offering integrates patient sourcing, iPSC derivation, brain cell differentiation, gene editing, 3D neurosphere culture, pharmacology assay development, and omics analysis, anchored by a portfolio of 200 fully characterized iPSC lines from Alzheimer's patients with associated clinical history and genotypic data, enabling client programs in patient stratification and targeted therapeutic development.

Product overview

StrataStem is a biotech company offering a unified platform of iPSC-based disease modeling services and therapeutic discovery solutions. The core offering consists of iPSC Disease Models for identifying disease mechanisms and novel drug targets, Companion Assays for phenotype validation, and Therapeutics Screening services for drug efficacy and toxicity assessment. These are supported by modular service capabilities including patient sourcing and tissue processing, iPSC derivation, brain cell type differentiation, 3D neurosphere and blood-brain barrier culture, gene editing, co-culture systems, omics analysis, and patient stratification. The company's Alzheimer's Disease iPSC Portfolio provides 200 fully characterized cell lines for research applications.

Differentiator

Problem solved

Functional benefit

Products and services

  • iPSC Disease Models Patient-derived induced pluripotent stem cell (iPSC) disease models delivered to pharmaceutical, biotechnology, and academic clients for use in disease mechanism studies, target validation, and preclinical drug discovery, with a particular focus on neurological and neurodegenerative diseases.
  • Companion Assays Custom-developed pharmacology and disease-relevant assays run on iPSC-derived cellular models, designed to support client preclinical programs in neurological disease research and therapeutic development.
  • Therapeutics Screening Therapeutic candidate screening services executed on StrataStem's iPSC-derived neuronal and neurological disease models, enabling clients to evaluate compounds for efficacy, toxicity, and mechanism of action in disease-relevant human cellular systems.
  • Alzheimer's Disease iPSC Portfolio A biobank offering of 200 fully characterized induced pluripotent stem cell lines derived from Alzheimer's disease patients, each annotated with clinical history and genotypic data, supplied to clients for use in patient stratification, target validation, and targeted therapeutic development.

Quantifiable outcome

  • 200 fully characterized iPSC lines with detailed patient clinical history and APOE genotyping

Companies that use StrataStem

Customer profile

Segments2 records

Ideal customer profiles2 records

StrataStem technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

StrataStem partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

StrataStem competitors and assessment

Company assessment

Broad incumbents

  • RoslinCT: A UK-based cell therapy and iPSC CDMO providing contract development and manufacturing services. Comparable as a UK-based iPSC services provider, though differentiated by CDMO focus versus StrataStem's discovery CRO model.
  • Crown Bioscience: A global CRO providing preclinical and translational drug discovery services including patient-derived models and in vitro screening. Adjacent to StrataStem through patient-derived disease modeling and drug screening services.
  • Fujifilm Cellular Dynamics: A major commercial supplier of iPSC-derived cell products and a provider of disease modeling services at scale. Competes with StrataStem through a much broader iPSC product portfolio and established pharma relationships.
  • Evotec: A large global drug discovery CRO offering iPSC-based disease modeling, high-content screening, and target validation across multiple therapeutic areas. Overlaps with StrataStem's discovery services but at significantly greater scale and breadth.

Emerging players

  • Cellectis: A gene editing company with strong capabilities in iPSC gene editing, including knockout/knock-in and TALEN-based editing. Overlaps with StrataStem's gene editing service module though focused on therapeutic development.
  • Reproductive Genetics Institute / iPSC service providers (e.g., CDI, Tempo Bioscience): Emerging iPSC platform companies offering patient-derived disease models and screening services. Comparable scale and indication focus to StrataStem as niche iPSC CROs serving pharma discovery.

Direct peers

  • Brainxell: A specialist provider of iPSC-derived neural cell types and neural differentiation services for CNS drug discovery. Directly comparable to StrataStem's brain cell differentiation and neurological disease modeling offering.
  • Ncardia: A European iPSC technology company offering iPSC-derived cell products and disease modeling services for drug discovery, including cardiac and neuronal applications. Direct competitor to StrataStem in iPSC-based disease models and contract screening services.
  • Axol Bioscience: A specialist iPSC-derived cell supplier focused on neural and cardiovascular cell types for drug discovery and disease modeling. Direct peer in iPSC-based disease models for neurological research applications.
  • Newcells Biotech: A UK-based contract research organization specializing in iPSC-derived models, including neural and kidney models, used for drug discovery and toxicity testing. Highly comparable CRO model and indication overlap with StrataStem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

StrataStem social profiles

Digital presence

StrataStem financial estimates

Financial estimate

Revenue estimate

Valuation estimate

StrataStem leadership team

Management profile

Number of profiles

Profiles3 records

StrataStem funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

StrataStem M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about StrataStem

What does StrataStem do?

StrataStem is a contract research organization that develops and supplies patient-derived induced pluripotent stem cell (iPSC) disease models and runs drug discovery and pharmacology screening services for neurological disease, with a focus on Alzheimer's disease. The company's offering integrates patient sourcing, iPSC derivation, brain cell differentiation, gene editing, 3D neurosphere culture, pharmacology assay development, and omics analysis, anchored by a portfolio of 200 fully characterized iPSC lines from Alzheimer's patients with associated clinical history and genotypic data, enabling client programs in patient stratification and targeted therapeutic development.

Is StrataStem a public or private company?

StrataStem is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was StrataStem founded?

StrataStem was founded in -1. It employs 1 to 10 people.

Where is StrataStem based?

StrataStem is headquartered in Macclesfield, United Kingdom, in the Europe region.

Who are StrataStem's main competitors?

Broad incumbents on record are RoslinCT, Crown Bioscience, Fujifilm Cellular Dynamics and Evotec. Emerging players are Cellectis and Reproductive Genetics Institute / iPSC service providers (e.g., CDI, Tempo Bioscience). Direct peers are Brainxell, Ncardia, Axol Bioscience and Newcells Biotech.

Does StrataStem have an API?

No public API is recorded for StrataStem.

What industry is StrataStem in?

StrataStem's product category is iPSC-based neurological drug discovery services. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAAAMAJ, Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales